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DOI 10.1016/j.chembiol.2010.08.003Here’s one truth about HIV: once infected,
always infected. Antiretroviral therapy
holds back active virus to undetectable
levels but never rids the body of HIV.
If people stop antiretroviral drugs, the
virus returns in full force, not from
new infection but from pools of HIV
hidden in plain sight in memory T cells,
the very immune defenders designed to
fight infection. These so-called latent
reservoirs stow away the virus in chemical
configurations that antiretroviral therapy
cannot touch.
Even though HAART (highly active anti-
retroviral therapy) allows people to live
with AIDS, there are drawbacks. It’s a
chronic therapy that requires strict com-
pliance. A person might miss one day of
medicine and suffer reinfection. PeopleEradicating the virus means getting every last memory T cell
activated and every last one of those cells has to die.on antiretroviral drugs for long periods
need to switch drugs because the
virus develops resistance. A recent study
shows that the health consequences of
HAART can include increased risk of
myocardial infarction (Lang et al., 2010).
Worldwide, billions of dollars are being
spent on HAART. Even with the flow of
money, fewer than half of the people
in Africa who need antiretroviral drugs
receive the therapy.
‘‘We’re facing a financial reality that we
knew would happen. We cannot sustain
the lifelong treatment of tens of millions
of people with antiretroviral therapy
throughout the world. This drives home
that we need to get individual persons
off of drugs, but can we cure AIDS?’’
asks Warner Greene, M.D., Ph.D.,
Director, Gladstone Institute of Virology
and Immunology.
The answer to that question may not be
far-fetched; for example, about 0.1%
of HIV-infected people spontaneously
control the virus to almost undetectable
levels. Scientists are trying to figure outhow this happens, but the fact that ‘‘elite
controllers’’ exist offers good news.
If scientists could find a way to reduce
the size of latent reservoirs more people
could come off medications. This ‘‘func-
tional cure’’ wouldn’t eradicate HIV but
would allow the immune response to
control what’s left of the virus.
For such a plan to work, researchers
would need to give people with HIV
a compound that wakes up memory
T cells harboring latent virus. Once acti-
vated, the cells turn into virus factories
and die within 24 hours. Meanwhile, the
antiretroviral drugs would prevent reinfec-
tion and thus avert any new reservoirs of
latent virus.
Stanford’s Paul Wender, Ph.D., says,
‘‘There’s been a whole lot of pessimismover the last five years that this is just
too big a problem and we won’t make
headway. But with failure of the vaccine
candidates, more and more effort and
attention has focused here. I think there’s
cause for optimism.’’
Other scientists share Wender’s enthu-
siasm. At least one compound shows
potential for activating memory T cells,
and researchers have good primate
models for latency.
Terrorism at a Cellular Level
Early clues to latent viral reservoirs came
in the 1980s on the heels of antiretroviral
therapy. The drugs slashed HIV to unde-
tectable levels, so people thought they
were free of disease and stopped therapy.
Within 4–6 weeks, the virus returned
full force. Clearly, there had to be some
source of disease that was not active
virus because the therapy kills off active
versions of HIV. ‘‘That’s when people
started to think about latency and realized
this gets encoded in the genome of
certain types of cells,’’ says Wender.Chemistry & Biology 17, August 27, 2010Tae-Wook Chun, Ph.D., of Anthony
S. Fauci’s lab at the National Institutes of
Health, began studying latency as part of
his doctoral thesis work. In two studies
published in 1997, he found the latent
virus in memory T cells of HIV-infected
people and provided an estimate of the
number of latent cells present in any given
individual (Chun et al., 1997a, 1997b).
The percentage of memory T cells that
harbor HIV is relatively small, about 1%.
Although the frequency is low, HIV needs
only one cell that gives rise to infectious
virus. That’s why HIV proves so hard to
eliminate. Unlike cytomegalovirus, an
example of a similar virus, HIV does not
have a gene that codes for latency. At
some point during an HIV infection, a
number of HIV-infected cells that were
pumping out lots of virus survived and
returned to a resting state. That’s how the
immune system works. Memory T cells
are trained to ‘‘remember’’ antigens to
which they were exposed so that they
can respond to future encounters with
the same antigen.
At this point, though, HIV is embedded
into a chromatin structure that is not
transcribed. Without transcription, DNA
is not expressed, so no viral proteins
appear on cell membranes and mark the
cell for immune destruction, nor do
infected resting T cells produce any virus.
Viral replication, however, resumes effi-
ciently once the same cell is activated
upon meeting a specific antigen it’s
trained to recognize. In HIV, the latent
virus slowly leaks out with a half-life esti-
mated to be 45 months; more than
50 years would be needed to deplete
reservoirs, says Wender. That’s why
researchers want to activate these cells
with a drug that quickly depletes the
virus. Unfortunately, the virus can
become latent before, during, and after
transcription.
Mauro Giacca, of Italy’s International
Centre for Genetic Engineering and Bio-
technology, recently showed the mecha-
nism for HIV pretranscription latency
(Manganaro et al., 2010). Scientistsª2010 Elsevier Ltd All rights reserved 787
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nonactivated T cells, but they never
knew why. Giacca’s recent Nature Medi-
cine paper shows that integrase, the
enzyme that integrates proviral DNA into
the host cell genome, doesn’t work in
nonactivated T cells, because such cells
lack the kinase to phosphorylate inte-
grase.Without phosphorylation, integrase
can’t undergo the change in shape that
allows HIV to integrate into the cell’s DNA.
Gone for Good?
That’s why HIV researchers are so keen to
find a way to activate resting T cells. One
such agent under investigation is prostra-
tin, a plant-derived small molecule that
comes from the bark of a tree found in
Samoa.Wender’sgroupatStanford found
a way to synthesize prostratin in the labo-
ratory andpublished the results inScience
(Wender et al., 2008). Now, Wender is
working with many groups to study the
prostratin analog, including the NIH and
the AIDS Research Alliance (http://www.
aidsresearch.org), a not-for-profit clinical
group that acquired rights to the technol-
ogy developed by Wender and colleagues
that allows AIDS researchers to synthesize
prostratin. ‘‘We can modify prostratin in a
way that gets rid of the side effects and
increases beneficial effects. Now we have
compounds that work much better than
prostratin,’’ says Wender.
In unpublished work, Wender’s group
took blood from patients with HIV/AIDS
on HAART therapy. In cell cultures, pros-
tratin converted latent virus formation to
the active virus and purged the viral reser-
voirs. This work so far has been done in
primates and in laboratory cultures and
not in humans. Wender hopes to conduct
phase I clinical trials in the next two years
or so that will test the drug’s safety.788 Chemistry & Biology 17, August 27, 2010At the NIH, Chun and colleagues are
also testing prostratin. However, Chun
has already tried a similar strategy
with IL-2, a potent stimulator of memory
T cells. In the late 1990s, Chun’s group
gave IL-2 to people with HIV. The treat-
ment worked. Latent T cells in HIV
patients who received IL-2 declined so
much that HAART therapy was stopped.
Unfortunately, the virus rebounded in
every patient (Chun et al., 1999). Chun
worries the same thing will happen with
prostratin or with similar agents. Eradi-
cating the virus means getting every last
memory T cell activated and every last
one of those cells has to die, and the
spread of virus produced by those cells
has to be stopped before HIV infects any
new cells.
Even that may not suffice. More and
more evidence shows that HIV reservoirs
can be found all over the body: in tissues
such as the gut and perhaps the brain.
New evidence shows that hematopoietic
stem cells can shelter HIV (Carter et al.,
2010). ‘‘Our knowledge about the extent
of these reservoirs is limited,’’ says
Chun. That’s why Chun says using one
agent to purge latent reservoirs may be
a long shot. He suggests a strategy that
tackles all three forms of latency simulta-
neously. Even if this strategy lowers the
HIV burden as much as 1 log, HIV likely
won’t be eradicated. For a functional
cure, the immune system will need to
keep any pools of the virus in check. Proof
will come later when patients stop therapy
and the virus doesn’t rebound for many
months or years.
‘‘You have to remember that we tried
IL-2 and other groups have tried anti-
CD3 antibody, an even more potent
T cell activator. All cases failed to eradi-
cate HIV,’’ says Chun. ‘‘You have to lookª2010 Elsevier Ltd All rights reservedat all of these things very carefully, but I
think it has to be done.’’REFERENCES
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